Legal Landscape Analysis

Three product classes, three legal tracks

People who compare peptides with steroids and SARMs often picture one scale running from legal to illegal. US federal law doesn't work that way. Each class falls under a different set of rules, and the legal risk lands on different people: on buyers as well as sellers for steroids, and mainly on sellers for the other two.

This page lays out that framework as of October 2026. It's the legal branch of our steroids, SARMs and peptides comparison hub, and the four articles under it each take one part of the subject further (there's a short guide near the end).

Anabolic steroids: controlled substances

Anabolic steroids are Schedule III controlled substances under the Controlled Substances Act. The DEA's Schedule III regulation names testosterone, nandrolone, trenbolone, stanozolol, oxandrolone and dozens of related compounds, including prohormones such as 4-androstenedione. It also covers "any substance meeting the definition of anabolic steroid," so a new analog doesn't escape just because it isn't named.

Scheduling is what puts the buyer at risk. Federal law makes it unlawful to possess a controlled substance without a valid prescription. A first simple-possession offense carries up to one year in prison and a minimum fine of $1,000, and the penalties rise after prior drug convictions. Testosterone and a few other steroids are also approved prescription medicines, so the same molecule can be lawful with a prescription and a federal crime without one.

SARMs: unapproved drugs, not scheduled

Selective androgen receptor modulators are not controlled substances. Congress has looked at scheduling them. The SARMs Control Act of 2019 (S. 2895) would have brought them under the controlled-substance framework, but it was referred to the Senate Judiciary Committee in November 2019 and never moved further. As of October 2026 we found no SARM-specific bill pending in the current Congress, so pages that describe SARMs as "pending scheduling" are out of date.

That doesn't make SARMs legal to sell for human use. No SARM is FDA-approved. USADA notes that doctors can't prescribe them and that they aren't legal ingredients in dietary supplements or compounded medicines. Enforcement runs through the Federal Food, Drug, and Cosmetic Act (FD&C Act), which targets the sale of unapproved and misbranded drugs, so the legal exposure sits mostly with sellers rather than with people who own a bottle.

Peptides: it depends on the peptide

"Peptides" covers several legally distinct groups:

• Approved prescription medicines, such as semaglutide or tesamorelin, are legal with a prescription filled by a licensed pharmacy.
• Compounded peptides can be prepared by a state-licensed pharmacy for an individual patient, but only if the bulk ingredient qualifies under section 503A of the FD&C Act.
• Unapproved peptides sold as "research use only" (RUO), such as BPC-157 or TB-500, make up most of the gray market.

Most peptides in that last group aren't controlled substances, so owning them isn't a federal crime in the way steroid possession is. The legal pressure falls on the supply chain instead.

What the research-use label does and doesn't do

Sellers rely on RUO and "not for human consumption" labels to argue that their products aren't drugs. FDA rejects that argument when other evidence points to human use. In an August 24, 2026 warning letter to one peptide seller, FDA said that despite those labels, the site's product descriptions and its sale of bacteriostatic water for reconstitution showed the products were meant for people, which made them unapproved new drugs. Health Canada's April 2026 advisory on injectable peptides makes the same point, saying the label "does not make these products legal or exempt from regulatory requirements."

The compounding route

As of October 2026, the compounding route is still closed for most of the popular gray-market peptides. In April 2026 FDA removed 12 peptides, including BPC-157 and TB-500, from Category 2 of its interim 503A list (the group flagged for significant safety risks) after their nominations were withdrawn. Removal didn't authorize compounding. It left them in no category at all.

In July 2026 FDA's Pharmacy Compounding Advisory Committee voted to recommend adding six of those peptides to the 503A bulks list, including BPC-157 by 8-6-1, over the objections of FDA staff. The vote is advisory. Putting a substance on the list takes notice-and-comment rulemaking, and as of early October 2026 we found no proposed rule. Even after listing, a peptide could only be compounded by a licensed pharmacy against a valid prescription. Legal commentators stress that none of this would make RUO consumer sales lawful.

Sport rules sit on top of the law

Anti-doping rules apply separately from drug law, and they cover tested athletes at every level, not only professionals. A compound can be legal to buy and still lead to a ban.

• SARMs are prohibited at all times under section S1.2 ("Other anabolic agents") of the WADA Prohibited List, according to USADA.
• Peptides: USADA lists BPC-157, TB-500, ipamorelin and ibutamoren (MK-677) among prohibited peptides. WADA's 2027 list, which takes effect January 1, 2027, adds "peptides" in general as an example in the S0 non-approved substances class.
• GLP-1 drugs: semaglutide and tirzepatide stay in WADA's Monitoring Program for 2027. Labs track them, but they aren't prohibited.

Under the World Anti-Doping Code athletes are strictly liable for what's in their sample, so a contaminated or mislabeled product counts the same as an intentional dose.

How the three compare

Where enforcement actually lands

The lines in that table blur in practice because gray-market products often aren't what the label says. In July 2026 the owner of Paradigm Peptides was sentenced to 70 months in federal prison after pleading guilty to selling unapproved drugs and illegally importing them, according to CBS News. When the government tested six of the company's products sold as SARMs, prosecutors said all six contained testosterone, a Schedule III steroid. So a buyer who thought they were taking an unscheduled SARM was, chemically, taking a controlled steroid.

The case was charged under the FD&C Act and import laws, not as a drug-trafficking case, which fits the wider pattern: federal action against peptide and SARM sellers has mostly meant warning letters and import seizures, with occasional prosecutions for selling unapproved drugs.

Where to go next

Each of the four articles under this page covers one part of the picture:

• Recent peptide enforcement trends looks at who federal agencies have targeted and why.
• The legal history of performance enhancers explains how steroid and prohormone laws developed, which helps explain why peptides ended up under drug law rather than drug scheduling.
• How other countries regulate peptides compares the US approach with other countries, including Canada and Australia.
• Predictions for future peptide regulation covers the open regulatory questions and how they might resolve.

What to watch next

• Whether FDA proposes a rule adding any of the six committee-backed peptides to the 503A bulks list. As of October 2026 none has been published.
• A second advisory committee meeting, planned before the end of February 2027, on GHK-Cu, melanotan II, LL-37, dihexa and PEG-MGF.
• The 2027 WADA Prohibited List, in force from January 1, 2027, and how anti-doping bodies apply its broader S0 wording on peptides.
• Any new attempt in Congress to schedule SARMs. None was pending as of October 2026.